Sudden Cardiac Arrest Panel
Use
This panel is intended to evaluate individuals—particularly young patients (<35 years)—who have suffered unexplained sudden cardiac arrest (SCA) or sudden cardiac death, where autopsy did not reveal a cause. Approximately one-third of such unexplained cases in the young may represent inherited arrhythmia disorders, including Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT).
Special Instructions
The test analyzes the complete coding regions and splice-site junctions of panel genes using a proprietary targeted capture system with NGS–CNV methods. When coverage is inadequate, alternative sequencing or copy number methods may be used to analyze or confirm specific regions. Reportable variants include pathogenic, likely pathogenic, and variants of uncertain significance; benign variants are not routinely reported but available upon request. If negative, sequencing and deletion/duplication analysis of the remaining genes on the larger arrhythmia panel may be ordered as a separate test.
Limitations
Technical limitations and inherent sequence properties may reduce resolution for some genes despite NGS coverage; some regions may require alternate methods. Likely benign and benign variants are not included in the report unless specifically requested. The panel may miss variants outside coding regions or deep intronic mutations.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Not provided
Minimum Volume
Not provided
Other tests from different labs that may be relevant